Compare PROF & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | HRZN |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.7M | 295.1M |
| IPO Year | 2017 | N/A |
| Metric | PROF | HRZN |
|---|---|---|
| Price | $5.82 | $4.23 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.00 | $6.67 |
| AVG Volume (30 Days) | 277.7K | ★ 1.3M |
| Earning Date | 03-05-2026 | 03-03-2026 |
| Dividend Yield | N/A | ★ 31.35% |
| EPS Growth | ★ 25.89 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $115.41 | $16.70 |
| Revenue Next Year | $60.63 | $22.34 |
| P/E Ratio | $3.67 | ★ N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.90 | $4.00 |
| 52 Week High | $8.95 | $9.52 |
| Indicator | PROF | HRZN |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 30.52 |
| Support Level | $5.38 | $4.00 |
| Resistance Level | $5.98 | $6.77 |
| Average True Range (ATR) | 0.52 | 0.18 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 48.63 | 41.59 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.